Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Insider Whittemore Tingley Sells 7,428 Shares

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) insider Whittemore Tingley sold 7,428 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $2.89, for a total transaction of $21,466.92. Following the completion of the transaction, the insider now directly owns 107,106 shares in the company, valued at approximately $309,536.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Tenaya Therapeutics Stock Performance

TNYA opened at $2.89 on Monday. The stock has a market cap of $226.92 million, a price-to-earnings ratio of -1.76 and a beta of 2.43. The firm’s fifty day moving average is $3.23 and its 200 day moving average is $4.28. Tenaya Therapeutics, Inc. has a fifty-two week low of $1.66 and a fifty-two week high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.06. On average, equities research analysts predict that Tenaya Therapeutics, Inc. will post -1.52 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on TNYA shares. William Blair began coverage on shares of Tenaya Therapeutics in a research report on Monday, June 10th. They issued an “outperform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Tenaya Therapeutics in a report on Monday, July 8th. Finally, Canaccord Genuity Group cut their price target on Tenaya Therapeutics from $18.00 to $16.00 and set a “buy” rating for the company in a report on Thursday, May 16th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $15.25.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TNYA. Vanguard Group Inc. raised its position in shares of Tenaya Therapeutics by 16.4% during the first quarter. Vanguard Group Inc. now owns 2,862,916 shares of the company’s stock valued at $14,973,000 after buying an additional 403,472 shares during the last quarter. RA Capital Management L.P. grew its stake in Tenaya Therapeutics by 4.5% during the first quarter. RA Capital Management L.P. now owns 5,755,050 shares of the company’s stock valued at $30,099,000 after acquiring an additional 247,703 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Tenaya Therapeutics by 144.1% in the 2nd quarter. Renaissance Technologies LLC now owns 157,460 shares of the company’s stock valued at $488,000 after acquiring an additional 92,960 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its stake in Tenaya Therapeutics by 90.8% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 168,565 shares of the company’s stock worth $882,000 after purchasing an additional 80,212 shares in the last quarter. Finally, Integral Health Asset Management LLC boosted its holdings in shares of Tenaya Therapeutics by 3.3% during the 2nd quarter. Integral Health Asset Management LLC now owns 2,325,000 shares of the company’s stock valued at $7,208,000 after purchasing an additional 75,000 shares during the last quarter. 90.54% of the stock is owned by hedge funds and other institutional investors.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.